Anosognosia

Summary

Anosognosia (MONDO:0000663) is a disease and 14 clinical trials. A subtype of agnosia — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 14

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	anosognosia
Mondo ID	MONDO:0000663
DOID	DOID:0060133
ICD-11	833222383
UMLS	C0234507
MedGen	536043
GARD	0027539
Is cancer (heuristic)	no

Disease family

This is a subtype of agnosia. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › nervous system disorder › perceptual disorders › agnosia › anosognosia

Related subtypes (19): akinetopsia, alexithymia, amusia, auditory agnosia, autotopagnosia, cortical deafness, finger agnosia, integrative agnosia, mirror agnosia, pain agnosia, phonagnosia, semantic agnosia, simultanagnosia, social emotional agnosia, astereognosia, tactile agnosia, time agnosia, visual agnosia, prosopagnosia

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 14.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	14

Top trials by phase / activity

NCT	Phase	Status	Title
NCT04845529	Not specified	NOT_YET_RECRUITING	Improving Awareness for Spatial Neglect With tDCS
NCT05500001	Not specified	RECRUITING	Supporting Patients by Family Education in Psychotic Illness: A Prospective Cohort Study
NCT06940882	Not specified	NOT_YET_RECRUITING	Development of a Novel Screening Tool for Anosognosia After Stroke.
NCT00908999	Not specified	COMPLETED	Functional Magnetic Resonance Imaging (fMRI) of Anosognosia in Amnestic Mild Cognitive Impairment (MCI) and Alzheimer’s Disease (AD)
NCT01469858	Not specified	UNKNOWN	Perception and Multisensory Integration in Neurological Patients Using fMRI
NCT02561715	Not specified	WITHDRAWN	Lack of Awareness of Symptoms (Anosognosia) in PD: An Observational Study for People With Parkinson’s
NCT02722070	Not specified	UNKNOWN	Processing Integration in Neurological Patients Using fMRI
NCT03712839	Not specified	COMPLETED	Cognitive-functional Evaluation of Anosognosia
NCT03958487	Not specified	COMPLETED	An Executive/Monitoring Treatment Protocol on Everyday Life Activities
NCT05145855	Not specified	COMPLETED	The Effects of Offline Anosognosia For Spatial Neglect on Neglect Rehabilitation
NCT05654350	Not specified	COMPLETED	Lesion Site and Neglect Anosognosia in Patients With Left Hemispatial Neglect
NCT05957484	Not specified	TERMINATED	The Effects of Non-invasive Neuromodulation on Illness Awareness in Schizophrenia
NCT06486584	Not specified	COMPLETED	Contingency Management for Problematic Behavior Reduction in the Community
NCT06794580	Not specified	COMPLETED	THE DUAL-SYSTEM HYPOTHESIS OF ANOSOGNOSIA: The Interplay Between Emotional Processing and Self-Monitoring in Neurodegenerative Patients